Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women

NCT04098900 | Completed

• 1 other identifier: TP-000279
• Study Type: observational
• Target: 309
• Locations: 1 country
• Sites: 5

Brief Summary

This study is a multi-center study with a minimum of three CLIA-waived intended operator sites in the United States in which prospectively self-collected vaginal specimens obtained from subjects who are symptomatic or asymptomatic for CT, NG, or TV will be evaluated with the Click Sexual Health Test in a Clinical Laboratory Improvement Amendments (CLIA) waived setting. Subjects interested in participating in this study will be assessed for eligibility and asked to give informed consent and assent, if applicable, by the Investigational Review Board (IRB). Only those subjects who meet the inclusion and exclusion criteria may be enrolled in the study.

Conditions

Chlamydial Infection; Gonococcal Infection; Trichomoniasis

Outcome Measures

Primary Outcomes (3)

• The percent sensitivity and specificity of the Click Device for detection of CT in self-collected vaginal specimens as compared to Patient Infected Status (PIS) using vaginal specimens collected by a qualified Health Care Provider (HCP)

  up to 6 months

• The percent sensitivity and specificity of the Click Device for detection of NG in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP

  up to 6 months

• The percent sensitivity and specificity of the Click Device for detection of TV in self-collected vaginal specimens as compared to PIS using vaginal specimens collected by a qualified HCP

  up to 6 months

Secondary Outcomes (1)

• Usability will be measured by 5-point Likert scale responses, yes/no questions, and open text questions from study operators.

  up to 6 months

Interventions

Click Sexual Health Test DIAGNOSTIC_TEST

The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.

Eligibility Criteria

• Age: 14 Years - 99 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population comprises female subjects greater than or equal to 14 years of age visiting any of the participating clinics for any reason, who may be symptomatic or asymptomatic for STIs at locations including but not limited to: OB/GYN and primary care offices, as well as sexually transmitted disease, teen, public health, and family planning clinics. Any subject who meets the inclusion/exclusion criteria is eligible to participate in this study.

You may qualify if:

• Willing and able to give voluntary written informed consent and assent form (or the parental/legal guardian will provide parental permission) before any study-related procedure is performed.
• Female at birth. (Pregnant and breastfeeding women are eligible).
• Age greater than or equal to 14 years at the time of enrollment
• Able to read and understand the procedural information provided for the study.
• Able and willing to follow all study procedures, including performing self-collection of one vaginal swab and permitting a HCP to collect three additional vaginal swabs.

You may not qualify if:

• Have a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgement, could jeopardize the subjects's safety, or could interfere with study procedures.
• Enrollment in the DMID 18-0024 and this study previously.
• Use of antiperspirants and deodorants or the following vaginal products: douches, washes, lubricants, vaginal wipes, vaginal moisturizers, or feminine hygiene spray in the genital area, within 48 hours prior to enrollment.

Sponsors & Collaborators

• Visby Medical: lead

Study Sites (5)

Therafirst Medical Center

Fort Lauderdale, Florida, 33308, United States

Location

Planned Parenthood North Central States

Saint Paul, Minnesota, 55114, United States

Location

Planned Parenthood of the St. Louis Region and Southwest Missouri

St Louis, Missouri, 63108, United States

Location

Lawrence OB/GYN Clinical Research, LLC

Lawrenceville, New Jersey, 08648, United States

Location

Planned Parenthood Gulf Coast

Houston, Texas, 77023, United States

Location

MeSH Terms

Conditions

Chlamydia Infections; Gonorrhea; Trichomonas Infections

Condition Hierarchy (Ancestors)

Chlamydiaceae Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Sexually Transmitted Diseases, Bacterial; Sexually Transmitted Diseases; Communicable Diseases; Genital Diseases; Urogenital Diseases; Neisseriaceae Infections; Protozoan Infections; Parasitic Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2019
• First Posted: September 23, 2019
• Study Start: September 16, 2019
• Primary Completion: December 3, 2019
• Study Completion: December 3, 2019
• Last Updated: February 17, 2020

Record last verified: 2019-09

Locations

US (5)